lapatinib has been researched along with prednisolone in 4 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (prednisolone) | Trials (prednisolone) | Recent Studies (post-2010) (prednisolone) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 34,414 | 3,302 | 7,141 |
| Protein | Taxonomy | lapatinib (IC50) | prednisolone (IC50) |
|---|---|---|---|
| Glucocorticoid receptor | Homo sapiens (human) | 0.0278 | |
| Progesterone receptor | Homo sapiens (human) | 2.08 | |
| Glucocorticoid receptor | Rattus norvegicus (Norway rat) | 0.0565 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.016 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0322 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.016 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.016 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for lapatinib and prednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for lapatinib and prednisolone
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |